Dongkook's record half was made in retail aisles, not in the lab

Dongkook Pharmaceutical said in a half-year report filed on the 14th that consolidated first-half sales reached 509.9 billion won ($367 million), its highest ever, with operating profit of 53.4 billion won ($38 million) ^[1][2]. What the company put forward as the driver was not a molecule but a shelf: an expanded online and offline network in its health-and-beauty unit, and a 566% year-on-year rise in second-quarter overseas sales of its dermacosmetic brand Centellian24 ^[7][8].

The headline growth rates are respectable rather than dramatic. Sales rose 11.5% and operating profit 12.6% ^[3][2], which works out to a 10.5% operating margin for the half ^[1]. Net profit rose 20.9% to 43.6 billion won ^[4], outpacing operating profit growth by 8.3 percentage points ^[2] on items the company did not itemise. Management attributes the margin improvement to higher sales plus better efficiency in selling and administrative expenses ^[6].

The pharmaceutical business grew, but it grew slower than the group. Prescription sales rose 10.5% in the second quarter and 9.4% for the half ^[9], the latter 2.1 points below the consolidated rate ^[6]. The named drivers are established products: the cholesterol treatment Atovan Duo, the osteoarthritis treatment Celebron and the peptic ulcer treatment Rabedon ^[9]. The health-functional-food business grew more than 40% in the half ^[10]. Neither the 566% nor the 40% comes with a base, and Dongkook did not disclose segment revenue, so the mix shift is directional rather than measurable from this filing ^[8][10].

One number in the release deserves more attention than the 566%. On a non-consolidated basis, sales rose 16.7% to 436.5 billion won and operating profit 23.4% to 47.8 billion won ^[5], both well ahead of the consolidated figures. Run the arithmetic backwards and everything outside the parent shrank: the sales gap between consolidated and non-consolidated fell from roughly 83 billion won to 73.4 billion won, about 12% ^[3][4], and the corresponding operating profit contribution fell from roughly 8.7 billion won to 5.6 billion won ^[5]. Consolidation eliminations sit inside those figures, so treat the magnitude loosely. The direction is still that the parent company carried this half.

The forward story is distribution, and the terms are undisclosed. Dongkook says it is expanding into Costco, Ulta Beauty and Nordstrom in the United States and Don Quijote and Loft in Japan, centred on Centellian24 ^[11]. In drugs, it is pushing overseas sales of Lorelin and Popol and has a licensing and supply agreement for Uresco, a combination treatment for benign prostatic hyperplasia, covering 13 countries in Latin America ^[12]. The pipeline discussion is about drug delivery system technology, with follow-on candidates including the microsphere prostate cancer treatment Lorelin plus obesity, acromegaly and immunosuppressant programmes ^[13]. No values, no dates.

Three things to watch. Whether the Centellian24 overseas comparison survives contact with a harder base in the second half, since 566% growth is roughly 6.7 times the prior-year quarter ^[7] and cannot repeat. Whether selling and administrative efficiency holds as a cosmetics brand pays for placement in North American and Japanese retail ^[6][11]. And whether the gap between parent and consolidated performance narrows, because a record half built on the parent while the rest of the group contracts is a narrower result than the top line suggests ^[5][5].